DEVELOPMENT AND EVALUATION OF ENTERIC COATED OMEPRAZOLE PELLETS 22.5% W/W

被引：0

作者：

Deepika, B. ^{[1
]}

Bikari, S. K. China ^{[2
]}

Kandukoori, Naga Raju ^{[1
]}

Thirupathi, A. Thanga ^{[3
]}

Sujatha, K. ^{[4
]}

机构：

[1] Nalanda Coll Pharm, Dept Pharmaceut, Nalgonda, TS, India

[2] Nalanda Coll Pharm, Dept Ind Pharm, Nalgonda, TS, India

[3] Nalanda Coll Pharm, Dept Pharmacol, Nalgonda, TS, India

[4] Sri Ramachandra Med Coll & Res Inst, Dept Pharmaceut Anal, Madras, Tamil Nadu, India

来源：

INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES | 2018年 / 5卷 / 07期

关键词：

Enteric coating; Delayed release; Omeprazole; Pellets;

D O I：

10.5281/zenodo.1307374

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The objective of the present study is to formulate and evaluate enteric coated delayed release pellets of Omeprazole. The formulations of Omeprazole delayed release pellets of were developed by enteric film coating process varying the compositions of drug loading, barrier coating and enteric coating. HPMC E5 was used as enteric polymer. The process variables were standardized and the different batches prepared were evaluated for assay/drug content, water content, acid resistance and dissolution rate. The drug dissolution profiles of Omeprazole delayed release formulations developed were compared with that of innovators product. Based on the results formulation containing enteric coating polymer and plasticizers has been selected as the best formulation developed for Omeprazole delayed release pellets.

引用

页码：6229 / 6235

页数：7

共 31 条

[1]

[Anonymous], 2013, DRUG METAB DISPOS, V41, P1414

[2]

[Anonymous], 2013, CMS MED INTEGRITY PR

[3] Gastric Acid Suppression by Proton Pump Inhibitors as a Risk Factor for Clostridium difficile-Associated Diarrhea in Hospitalized Patients [J].

Aseeri, Mohammed ;

Schroeder, Todd ;

Kramer, Joan ;

Zackula, Rosalee .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (09) :2308-2313

[4]

Baselt RC, 2008, DISPOSITION TOXIC DR, P1146

[5] Proton pump inhibitor therapy and potential long-term harm [J].

Corleto, Vito Domenico ;

Festa, Stefano ;

Di Giulio, Emilio ;

Annibale, Bruno .

CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2014, 21 (01) :3-8

[6] Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease [J].

Dial, S ;

Delaney, JAC ;

Barkun, AN ;

Suissa, S .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (23) :2989-2995

[7] Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs [J].

Douglas, Ian J. ;

Evans, Stephen J. W. ;

Hingorani, Aroon D. ;

Grosso, Anthony M. ;

Timmis, Adam ;

Hemingway, Harry ;

Smeeth, Liam .

BMJ-BRITISH MEDICAL JOURNAL, 2012, 345

[8]

Fitzakerley Janet, 2014, PPIS SIDE EFFECTS

[9] Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review [J].

Focks, Jeroen Jaspers ;

Brouwer, Marc A. ;

van Oijen, Martijn G. H. ;

Lanas, Angel ;

Bhatt, Deepak L. ;

Verheugt, Freek W. A. .

HEART, 2013, 99 (08) :520-527

[10] Meta-analysis:: duration of first-line proton-pump inhibitor-based triple therapy for Helicobacter pylori eradication [J].

Fuccio, Lorenzo ;

Minardi, Maria Eugenia ;

Zagari, Rocco Maurizio ;

Grilli, Diego ;

Magrini, Nicola ;

Bazzoli, Franco .

ANNALS OF INTERNAL MEDICINE, 2007, 147 (08) :553-562

← 1 2 3 4 →